Instead, many studies have indicated that TLR agonists alone may have detrimental clinical effects by creating an inflammatory environment favourable for tumour growth, although whether the effects promote or inhibit tumour growth appears to depend on the specific TLR7. This evidence concerns the gene TLR7 and neoplasm.